Species distribution and drug susceptibilities of Candida isolates in TSARY 2010

Diagn Microbiol Infect Dis. 2013 Jun;76(2):182-6. doi: 10.1016/j.diagmicrobio.2013.03.003. Epub 2013 Apr 8.

Abstract

Susceptibilities to antifungal drugs of 1083 Candida isolates collected in Taiwan Surveillance of Antimicrobial Resistance of Yeasts in 2010 were determined. There were 422 (39%) C. albicans, 270 (24.9%) C. tropicalis, 258 (23.8%) C. glabrata, 87 (8%) C. parapsilosis, 18 (1.7%) C. krusei, and 28 (2.6%) of 13 other species. In the present study, we have applied species-specific clinical breakpoints for common species and epidemiological cutoff values for rare species. We found that majority of isolates were susceptible to tested drugs. A total of 15, 3, 2, and 0 isolates were not susceptible to fluconazole, voriconazole, amphotericin B, and anidulafungin, respectively. We found that three of the four fluconazole non-susceptible C. albicans isolates were resistant to voriconazole. Hence, there is an issue of cross-resistance among azole-type drugs.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / pharmacology
  • Anidulafungin
  • Antifungal Agents / pharmacology*
  • Azoles / pharmacology
  • Candida / classification*
  • Candida / drug effects
  • Candida / isolation & purification*
  • Drug Resistance, Multiple, Fungal*
  • Echinocandins / pharmacology
  • Fluconazole / pharmacology
  • Hospitals
  • Humans
  • Microbial Sensitivity Tests
  • Pyrimidines / pharmacology
  • Taiwan
  • Triazoles / pharmacology
  • Voriconazole

Substances

  • Antifungal Agents
  • Azoles
  • Echinocandins
  • Pyrimidines
  • Triazoles
  • Amphotericin B
  • Fluconazole
  • Anidulafungin
  • Voriconazole